3 completed, 1 terminated, 1 withdrawn. 2 Phase 1, 2 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 2 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Atrioventricular Septal Defect: new trials by email Literature Review of Atrioventricular Septal Defect trials Research Report on Atrioventricular Septal Defect
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects L-citrulline, Plasmalyte A - Ventricular Septal Defect, Atrioventricular Septal Defect | Phase 3 | Terminated | Asklepion Pharmaceuticals, LLC | 64 | 2022-06-29 | 2024-09-19 |
| Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow IV L-carnitine - Heart Septal Defects, Ventricular, Atrioventricular Septal Defect | Phase 1 | Withdrawn | University of California, San Francisco | 2014-12-01 | 2020-05-06 | |
| Acetaminophen for Oxidative Stress After Cardiopulmonary Bypass Acetaminophen - Congenital Heart Disease, Cardiopulmonary Bypass | Not applicable | Completed | Vanderbilt University Medical Center | 30 | 2011-07-01 | 2017-04-21 |
| Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol Intravenous L-Citrulline, Placebo of Intravenous L-Citrulline - Atrial Septal Defect, Ventricular Septal Defect | Phase 1 / Phase 2 | Completed | Asklepion Pharmaceuticals, LLC | 22 | 2010-09-01 | 2022-07-27 |
| Measures to Lower the Stress Response in Pediatric Cardiac Surgery Fentanyl (High Dose), Fentanyl (Low Dose), Fentanyl (Low Dose) + Dexmedetomidine - Tetralogy of Fallot (TOF), Ventricular Septal Defects (VSD) | Phase 2 | Completed | Nationwide Children's Hospital | 52 | 2008-11-01 | 2018-07-27 |
Heart Septal Defects, Ventricular (5) · Heart Defects, Congenital (2) · Acute Kidney Injury (1) · Endocardial Cushion Defects (1) · Fractures, Stress (1) · Heart Septal Defects, Atrial (1) · Hemolysis (1) · Partial atrioventricular canal (1) · Tetralogy of Fallot (1)
Cardiovascular Abnormalities (5) · Cardiovascular Diseases (5) · Congenital Abnormalities (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Heart Diseases (5) · Heart Septal Defects (5) · Heart Defects, Congenital (3) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Fractures, Bone (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Renal Insufficiency (1)
Acetaminophen (1) · Carnitine (1) · Citrulline (1) · Dexmedetomidine (1) · Fentanyl (1) · Plasmalyte A (1)
Asklepion Pharmaceuticals, LLC (2) · Nationwide Children's Hospital (1) · University of California, San Francisco (1) · Vanderbilt University Medical Center (1)
United States (5)
Allan Doctor, MD (1) · Aymen N Naguib, MD (1) · Catherine Krawczeski, MD (1) · Christopher Mastropietro, MD, FCCM (1) · Frederick E Barr, MD (1) · Gurdyal Kalsi, MD, MFPM (1) · Jeffrey Fineman, MD (1) · Scott A Simpson, MD (1)